Tandem Diabetes Care Inc

Mark Novara’s insider trades show confidence in Tandem Diabetes Care’s insulin‑pump pipeline, reflecting disciplined buying amid a strong rally and suggesting undervalued growth potential.

Insider buying signals confidence: Mark David’s February 17 purchase of Tandem Diabetes Care shares shows executives staying invested amid a 40% YTD decline, hinting at long‑term optimism for its insulin‑delivery platform.

Senior executive buying Tandem Diabetes shares signals confidence in the company’s long‑term growth and robust insulin‑delivery tech.